

SUPPLEMENTAL MATERIAL

Supplemental Table 1A. Prevalent, concurrent and future AF in 1166 HF participants (HFpEF vs HFrEF vs unclassified HF)

		No AF	Prevalent AF	Concurrent AF	Future AF
HFpEF (n=479)	n	181	154	88	56
	%	38	32	18	12
HFrEF (n=516)	n	234	121	94	67
	%	45	23	18	13
Unclassified HF (n=171)	n	87	42	32	10
	%	51	25	19	6
Total HF (n=1166)	n	502	317	214	133
	%	43	27	18	11

AF = atrial fibrillation; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.

Supplemental Table 1B. Previous, concurrent and future HF (HFpEF vs HFrEF vs unclassified HF) in those who had 1737 AF

		No HF	Prevalent HF	Concurrent HF	Future HF
Total AF (n=1737)	n	1101	145	214	277
	%	63	8	12	16
HFpEF	n		57	88	139
	%		3	5	8
HFrEF	n		67	94	111
	%		4	5	6
Unclassified HF	n		21	32	27
	%		1	2	2

AF = atrial fibrillation; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.

Supplemental Table 2. Baseline characteristics of participants included in mortality analysis

	HF N=759	HFpEF N=309	HFrEF N=360	AF N=1191
Age, years	78±10	79 ± 11	77 ± 10	75 ± 11
Women, n (%)	355 (47)	182 (59)	123 (34)	514 (43)
Height, cm	164 ± 11	162 ± 11	166 ± 10	166 ± 11
Weight, kg	75 ± 18	75 ± 19	77 ± 17	77 ± 18
Body mass index, kg/m ²	28 ± 5	29 ± 6	28 ± 5	28 ± 5
Systolic blood pressure, mmHg	143 ± 22	142 ± 21	143 ± 23	140 ± 22
Diastolic blood pressure, mmHg	73 ± 12	73 ± 11	73 ± 12	74 ± 11
Hypertension treatment, n (%)	492 (65)	222 (72)	221 (61)	664 (56)
Prevalent myocardial infarction, n (%)	321 (42)	86 (28)	196 (54)	274 (23)
Smoking, n (%)	110 (14)	41 (13)	58 (16)	177 (15)
Diabetes mellitus, n (%)	196 (26)	73 (24)	106 (29)	201 (17)
Left ventricular hypertrophy, n (%)	70 (10)	21 (7)	40 (12)	55 (5)
Prevalent HF, n (%)	-	-	-	214 (18)
Prevalent AF, n (%)	295 (39)	128 (41)	130 (36)	-

Values are mean ± SD unless otherwise noted.

AF = atrial fibrillation; HF = heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction.

Supplemental Table 3. Sex-specific, age-standardized incident rates of HF among those with AF

	Men	Women
	Incidence rate per 1000 person-years (95% CI)	Incidence rate per 1000 person-years (95% CI)
Incident HF	50.7 (41.9, 59.6)	56.0 (45.5, 66.6)
Incident HFpEF	21.2 (15.3, 27.0)	35.1 (26.9, 43.4)
Incident HFrEF	27.2 (20.8, 33.5)	12.4 (7.4, 17.4)

CI=confidence interval; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction.

Supplemental Table 4. Incidence rates of cause-specific death among participants with AF

	Coronary heart disease death	Cerebrovascular death	Other cardiovascular death
	Incidence rates (95% CI)	Incidence rates (95% CI)	Incidence rates (95% CI)
No heart failure	11.62 (8.44-14.80)	8.58 (5.88-11.28)	14.82 (11.18-18.47)
HFpEF	14.38 (1.45-27.31)	18.80 (3.61-33.99)	52.19 (26.20-78.18)
HFrEF	95.65 (57.87-133.4)	7.63 (-1.10-16.35)	85.15 (50.84-119.5)

CI=confidence interval; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction.

Supplemental Table 5. Cumulative incidence and 95% confidence intervals for Figures 2 and 3

Outcome	Group	Year 4 cumulative incidence (%)		Year 8 cumulative incidence (%)	
		Est	95% CI	Est	95% CI
Incident AF (Fig 2A)	Prev HF	0.11	(0.06-0.19)	0.20	(0.12-0.29)
	No HF	0.02	(0.02-0.03)	0.05	(0.05-0.06)
Incident HFPEF (Fig 2B)	Prev AF	0.03	(0.02-0.06)	0.07	(0.05-0.10)
	No AF	0.01	(0.00-0.01)	0.01	(0.01-0.01)
Incident HFREF (Fig 2B)	Prev AF	0.05	(0.03-0.07)	0.08	(0.05-0.11)
	No AF	0.01	(0.01-0.01)	0.02	(0.01-0.02)
Mortality after HF (Fig 3A)	Prev AF	0.57	(0.51-0.62)	0.83	(0.78-0.87)
	No AF	0.56	(0.51-0.60)	0.77	(0.72-0.80)
Mortality after AF (Fig 3B)	Prev HFpEF	0.53	(0.42-0.63)	0.78	(0.66-0.86)
	Prev HFrEF	0.63	(0.54-0.71)	0.86	(0.78-0.91)
	No HF	0.31	(0.28-0.34)	0.51	(0.47-0.54)

Supplemental Figure legends

Supplemental Figure 1: Study design

Panel A displays participants free of prevalent AF.

Panel B displays participants free of prevalent HF

Supplemental Figure 2: Inclusion and exclusion criteria for study sample.

Panel A shows samples included in the incident AF and HF analyses.

Panel B shows samples included in the mortality after AF and HF analyses.


Supplemental Figure 3: Time between diagnosis of AF and HF diagnosis (years)

Panel A displays time between diagnosis of AF and HFpEF.


Panel B displays time between diagnosis of AF and HFrEF. Zero represents AF and HF diagnosis on the same day.

Supplemental Figure 1

A.




B.




Supplemental Figure 2

A.




B.



Supplemental Figure 3

A.



B.

